Axxcess Wealth Management LLC Has $3.99 Million Stock Holdings in Bristol-Myers Squibb (NYSE:BMY)

Axxcess Wealth Management LLC lifted its stake in shares of Bristol-Myers Squibb (NYSE:BMY) by 22.3% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 73,554 shares of the biopharmaceutical company’s stock after purchasing an additional 13,414 shares during the quarter. Axxcess Wealth Management LLC’s holdings in Bristol-Myers Squibb were worth $3,989,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Northwest Financial Advisors acquired a new stake in shares of Bristol-Myers Squibb during the 4th quarter valued at $27,000. ESL Trust Services LLC purchased a new stake in shares of Bristol-Myers Squibb in the first quarter worth approximately $27,000. Accordant Advisory Group Inc bought a new stake in Bristol-Myers Squibb during the first quarter worth $31,000. Pacific Capital Wealth Advisors Inc. purchased a new position in Bristol-Myers Squibb in the fourth quarter worth $34,000. Finally, Turtle Creek Wealth Advisors LLC purchased a new stake in shares of Bristol-Myers Squibb in the fourth quarter worth about $40,000. Institutional investors own 76.41% of the company’s stock.

Analyst Upgrades and Downgrades

BMY has been the topic of several recent analyst reports. Barclays lowered their price target on Bristol-Myers Squibb from $43.00 to $41.00 and set an “equal weight” rating on the stock in a report on Wednesday, July 10th. William Blair reiterated a “market perform” rating on shares of Bristol-Myers Squibb in a research report on Monday, April 1st. StockNews.com cut Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research note on Thursday, June 27th. Wells Fargo & Company upped their price target on Bristol-Myers Squibb from $51.00 to $52.00 and gave the company an “equal weight” rating in a research report on Thursday, April 18th. Finally, Cantor Fitzgerald reiterated a “neutral” rating and issued a $45.00 price objective on shares of Bristol-Myers Squibb in a research report on Monday. One research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $57.73.

Bristol-Myers Squibb Stock Up 11.4 %

Shares of BMY stock traded up $5.18 during mid-day trading on Friday, hitting $50.45. The stock had a trading volume of 35,840,609 shares, compared to its average volume of 15,913,001. The firm has a market capitalization of $102.27 billion, a P/E ratio of -15.75, a price-to-earnings-growth ratio of 16.73 and a beta of 0.44. Bristol-Myers Squibb has a 12-month low of $39.35 and a 12-month high of $63.41. The company has a debt-to-equity ratio of 2.99, a current ratio of 1.11 and a quick ratio of 0.99. The firm’s 50-day moving average is $41.63 and its two-hundred day moving average is $46.83.

Bristol-Myers Squibb (NYSE:BMY) last posted its earnings results on Friday, July 26th. The biopharmaceutical company reported $2.07 EPS for the quarter, beating analysts’ consensus estimates of $1.67 by $0.40. The company had revenue of $12.20 billion during the quarter, compared to analysts’ expectations of $11.54 billion. Bristol-Myers Squibb had a negative net margin of 13.50% and a positive return on equity of 8.83%. Bristol-Myers Squibb’s revenue for the quarter was up 8.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.75 earnings per share. On average, analysts predict that Bristol-Myers Squibb will post 0.53 earnings per share for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, August 1st. Shareholders of record on Friday, July 5th will be issued a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a yield of 4.76%. The ex-dividend date of this dividend is Friday, July 5th. Bristol-Myers Squibb’s payout ratio is presently -77.42%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.